Summit Therapeutics plc Stock
-
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
Cons
Performance of Summit Therapeutics plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Proteome Sciences | 57.690% | 57.692% | 28.125% | -34.921% | -29.310% | -37.879% | -12.766% |
| Oxford BioMedica PLC | -0.710% | -0.709% | -7.895% | 40.562% | 37.255% | 50.862% | -24.731% |
| Sareum Holdings plc | -3.820% | -4.545% | -12.500% | -59.615% | -58.278% | -86.452% | - |
News
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?
Did you know that Summit Therapeutics (NASDAQ: SMMT) is one of the few publicly traded companies that has a market cap of more than $10 billion, but no revenue? With that kind of a valuation and
Don't Buy Summit Therapeutics Until This Big Thing Happen
Sometimes, everything can seem to be going your way. And then the wheels fall off. That's the situation Summit Therapeutics (NASDAQ: SMMT) finds itself in.
Shares of the clinical-stage biotech
2 Monster Stocks in the Making to Buy and Hold
It's not possible to go back in time and invest in Nvidia or Amazon when they were still relatively small companies. However, it is possible to identify corporations that appear poised to establish


